EMD Serono and Mersana Therapeutics entered an agreement to develop next-generation antibody-drug conjugates (ADCs) leveraging Mersana’s Fleximer technology for multiple undisclosed targets. Both companies will test a variety of ADCs and several cytotoxic agents as conjugates.   EMD Serono will provide monoclonal antibodies and Mersana will generate the Fleximer-ADCs and conduct discovery and preclinical development activities. EMD Serono will be responsible for clinical development and co...